Effects of lower-cost incentives on stimulant abstinence in methadone maintenance treatment - A national drug abuse treatment clinical trials network study

被引:249
|
作者
Peirce, JM
Petry, NM
Stitzer, ML
Blaine, J
Kellogg, S
Satterfield, F
Schwartz, M
Krasnansky, J
Pencer, E
Silva-Vazquez, L
Kirby, KC
Roger-Malvestuto, C
Roll, JM
Cohen, A
Copersino, ML
Kolodner, K
机构
[1] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[2] Univ Connecticut, Sch Med, New Haven, CT USA
[3] Biopharmaceut Res Consultants Inc, Ann Arbor, MI USA
[4] NYU, New York, NY USA
[5] Rockefeller Univ, New York, NY 10021 USA
[6] Univ Penn, Philadelphia, PA 19104 USA
[7] Treatment Res Inst, Philadelphia, PA USA
[8] Washington State Univ, Washington Inst Mental Illness Res & Training, Spokane, WA USA
[9] Univ Calif Los Angeles, Los Angeles, CA USA
[10] NIDA, Intramural Res Program, Baltimore, MD USA
关键词
D O I
10.1001/archpsyc.63.2.201
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: Contingency management interventions that provide tangible incentives based on objective indicators of drug abstinence have improved treatment outcomes of substance abusers, but have not been widely implemented in community drug abuse treatment settings. Objective: To compare outcomes achieved when a lower-cost prize-based contingency management treatment is added to usual care in community methadone hydrochloride maintenance treatment settings. Design: Random assignment to usual care with (n = 198) or without (n = 190) abstinence incentives during a 12-week trial. Setting: Six community-based methadone maintenance drug abuse treatment clinics in locations across the United States. Participants: Three hundred eighty-eight stimulant-abusing patients enrolled in methadone maintenance programs for at least 1 month and no more than 3 years. Intervention: Participants submitting stimulant- and alcohol-negative samples earned draws for a chance to win prizes; the number of draws earned increased with continuous abstinence time. Main Outcome Measures: Total number of stimulant- and alcohol-negative samples provided, percentage of stimulant- and alcohol-negative samples provided, longest duration of abstinence, retention, and counseling attendance. Results: Submission of stimulant- and alcohol-negative samples was twice as likely for incentive as for usual care group participants (odds ratio, 1.98; 95% confidence interval, 1.42-2.77). Achieving 4 or more, 8 or more, and 12 weeks of continuous abstinence was approximately 3, 9, and 11 times more likely, respectively, for incentive vs usual care participants. Groups did not differ on study retention or counseling attendance. The average cost of prizes was $120 per participant. Conclusion: An abstinence incentive approach that paid $120 in prizes per participant effectively increased stimulant abstinence in community-based methadone maintenance treatment clinics.
引用
收藏
页码:201 / 208
页数:8
相关论文
共 50 条
  • [31] Standardized Patient Walkthroughs in the National Drug Abuse Treatment Clinical Trials Network: Common Challenges to Protocol Implementation
    Fussell, Holly E.
    Kunkel, Lynn E.
    McCarty, Dennis
    Lewy, Colleen S.
    AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, 2011, 37 (05): : 434 - 439
  • [32] The National Drug Abuse Treatment Clinical Trials Network: forging a partnership between research knowledge and community practice
    Tai, Betty
    Sparenborg, Steven
    Liu, David
    Straus, Michele
    SUBSTANCE ABUSE AND REHABILITATION, 2011, 2 : 21 - 28
  • [33] Stimulant abuser groups to engage in 12-Step: A multisite trial in the National Institute on Drug Abuse Clinical Trials Network
    Donovan, Dennis M.
    Daley, Dennis C.
    Brigham, Gregory S.
    Hodgkins, Candace C.
    Perl, Harold I.
    Garrett, Sharon B.
    Doyle, Suzanne R.
    Floyd, Anthony S.
    Knox, Patricia C.
    Botero, Christopher
    Kelly, Thomas M.
    Killeen, Therese K.
    Hayes, Carole
    Kau'iBaumhofer, Nicole
    Seamans, Cindy
    Zammarelli, Lucy
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2013, 44 (01) : 103 - 114
  • [34] Using a health information technology survey to explore the availability of addiction treatment data in the electronic health records: A National Drug Abuse Treatment Clinical Trials Network study
    Wu, Li-Tzy
    Payne, Elizabeth H.
    Roseman, Kimberly
    Case, Ashley
    Nelson, Casey
    Lindblad, Robert
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2020, 112 : 56 - 62
  • [35] Research priorities for expanding access to methadone treatment for opioid use disorder in the United States: A National Institute on Drug Abuse Center for Clinical Trials Network Task Force report
    Joudrey, Paul J.
    Bart, Gavin
    Brooner, Robert K.
    Brown, Lawrence
    Dickson-Gomez, Julie
    Gordon, Adam
    Kawasaki, Sarah S.
    Liebschutz, Jane M.
    Nunes, Edward
    McCarty, Dennis
    Schwartz, Robert P.
    Szapocnik, Jose
    Trivedi, Madhukar
    Tsui, Judith, I
    Williams, Arthur
    Wu, Li-Tzy
    Fiellin, David A.
    SUBSTANCE ABUSE, 2021, 42 (03) : 245 - 254
  • [36] The application of digital health to the assessment and treatment of substance use disorders: The past, current, and future role of the National Drug Abuse Treatment Clinical Trials Network
    Marsch, Lisa A.
    Campbell, Aimee
    Campbell, Cynthia
    Chen, Ching-Hua
    Ertin, Emre
    Ghitza, Udi
    Lambert-Harris, Chantal
    Hassanpour, Saeed
    Holtyn, August F.
    Hser, Yih-Ing
    Jacobs, Petra
    Klausner, Jeffrey D.
    Lemley, Shea
    Kotz, David
    Meier, Andrea
    McLeman, Bethany
    McNeely, Jennifer
    Mishra, Varun
    Mooney, Larissa
    Nunes, Edward
    Stafylis, Chrysovalantis
    Stanger, Catherine
    Saunders, Elizabeth
    Subramaniam, Geetha
    Young, Sean
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2020, 112 : 4 - 11
  • [37] The National Drug Abuse Treatment Clinical Trials Network Data Share project: Website design, usage, challenges, and future directions
    Shmueli-Blumberg, Dikla
    Hu, Lian
    Allen, Colleen
    Frasketi, Michael
    Wu, Li-Tzy
    VanVeldhuisen, Paul
    CLINICAL TRIALS, 2013, 10 (06) : 977 - 986
  • [38] Expanding the National Drug Abuse Treatment Clinical Trials Network to address the management of substance use disorders in general medical settings
    Tai, Betty
    Sparenborg, Steven
    Ghitza, Udi E.
    Liu, David
    SUBSTANCE ABUSE AND REHABILITATION, 2014, 5 : 75 - 80
  • [39] Opioid Use Disorder in Women: Evidence from the National Institute on Drug Abuse Clinical Trials Network (CTN) and the Implications for Treatment
    Greenfield, Shelly
    Rosa, Carmen
    Barbosa-Leiker, Celestina
    Campbell, Aimee
    McHugh, Kathryn
    Guille, Constance
    Ouseph, Rita
    Sise, Robert
    AMERICAN JOURNAL ON ADDICTIONS, 2019, 28 (03): : 162 - 162
  • [40] Is telemedicine the answer to rural expansion of medication treatment for opioid use disorder? Early experiences in the feasibility study phase of a National Drug Abuse Treatment Clinical Trials Network Trial
    Hser, Yih-Ing
    Ober, Allison J.
    Dopp, Alex R.
    Lin, Chunqing
    Osterhage, Katie P.
    Clingan, Sarah E.
    Mooney, Larissa J.
    Curtis, Megan E.
    Marsch, Lisa A.
    McLeman, Bethany
    Hichborn, Emily
    Lester, Laurie S.
    Baldwin, Laura-Mae
    Liu, Yanping
    Jacobs, Petra
    Saxon, Andrew J.
    ADDICTION SCIENCE & CLINICAL PRACTICE, 2021, 16 (01)